Early research (Phase 1)Study completedNCT01551524What this trial is testingPhase I Study of mPEG-R-Crisantaspase Given IVWho this might be right forHematologic Malignancies Jazz Pharmaceuticals 36
Testing effectiveness (Phase 2)Study completedNCT00003913What this trial is testingUmbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic DiseaseWho this might be right forLeukemiaLymphomaMyelodysplastic Syndromes+1 more Fred Hutchinson Cancer Center 390
Testing effectiveness (Phase 2)Study completedNCT03097770What this trial is testingTreatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20Who this might be right forHematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic Leukemia+20 more Chinese PLA General Hospital 100
Early research (Phase 1)Study completedNCT04136756What this trial is testingNKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaWho this might be right forMultiple MyelomaNon-Hodgkin LymphomaIndolent Non-Hodgkin Lymphoma Nektar Therapeutics 30
Testing effectiveness (Phase 2)UnknownNCT03185494What this trial is testingTreatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22Who this might be right forHematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic Leukemia+20 more Chinese PLA General Hospital 30
Testing effectiveness (Phase 2)Study completedNCT01447914What this trial is testingTivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple MyelomaWho this might be right forRefractory Multiple Myeloma National Cancer Institute (NCI) 16
Testing effectiveness (Phase 2)Study completedNCT00732316What this trial is testingDonor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic SyndromeWho this might be right forLeukemiaMyelodysplastic Syndromes Asan Medical Center 54
Early research (Phase 1)Looking for participantsNCT05735184What this trial is testingInvestigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLWho this might be right forAcute Myeloid LeukemiaMixed Lineage Leukemia Gene MutationRefractory AML+7 more Kura Oncology, Inc. 420
Early research (Phase 1)Study completedNCT01300026What this trial is testingAMG 319 Lymphoid Malignancy FIHWho this might be right forCancerChronic Lymphocytic LeukemiaDiffuse Large Cell Lymphoma+11 more Amgen 28
Testing effectiveness (Phase 2)Study completedNCT00109707What this trial is testingOral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic MalignanciesWho this might be right forChronic Myelogenous LeukemiaAcute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)Hypereosinophilic Syndrome+1 more Novartis Pharmaceuticals 507
Early research (Phase 1)Looking for participantsNCT07106749What this trial is testingCD180 CART for Relapsed or Refractory CD180 Positive Hematologic MalignanciesWho this might be right forAcute Myeloid LeukemiaB Acute Lymphoblastic Leukemia/Lymphoma Institute of Hematology & Blood Diseases Hospital, China 12
Testing effectiveness (Phase 2)WithdrawnNCT05205252What this trial is testingTazemetostat in Combination With Various Treatments in Participants With Blood Cancer.Who this might be right forRelapsed Hematologic MalignancyRefractory Hematologic Malignancy Epizyme, Inc.
Very early researchUnknownNCT04011293What this trial is testingA Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell MalignanciesWho this might be right forRelapsed or Refractory Hematological Malignancies Shandong University 20
Not applicableNo Longer AvailableNCT00423826What this trial is testingUmbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseaseWho this might be right forLeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+3 more Barbara Ann Karmanos Cancer Institute
Early research (Phase 1)Not Yet RecruitingNCT07113496What this trial is testingRN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic MalignanciesWho this might be right forRelapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more The First Affiliated Hospital with Nanjing Medical University 27
Early research (Phase 1)Study completedNCT04926285What this trial is testingSafety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)Who this might be right forRelapsed or Refractory Hematologic Malignancies University of Illinois at Chicago 6
Early research (Phase 1)Looking for participantsNCT03113643What this trial is testingSL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Who this might be right forAcute Myeloid LeukemiaMyelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm Dana-Farber Cancer Institute 72
Very early researchUnknownNCT04226989What this trial is testingCT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological MalignancyWho this might be right forAcute Lymphoblastic LeukemiaNon-Hodgkin's Lymphoma He Huang 72
Early research (Phase 1)Study completedNCT00904787What this trial is testingStudy of ENMD-2076 in Patients With Relapsed or Refractory Hematological MalignanciesWho this might be right forRelapsed or Refractory Hematological Malignancies CASI pharmaceuticals, Inc. 27
Early research (Phase 1)Study completedNCT02543879What this trial is testingStudy of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic MalignanciesWho this might be right forAcute Myeloid LeukemiaAcute Myelogenous LeukemiaMyelodysplastic Syndrome+1 more Forma Therapeutics, Inc. 94